ArticleiLIVER2022
Clinical analysis of the characteristics of patients diagnosed with hemolytic anemia induced by hepatitis E viral infection.
Article in iLIVER, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The extrahepatic manifestations of hepatitis E virus (HEV) infection include hemolytic anemia. However, the clinical characteristics of HEV-induced hemolytic anemia have been only sporadically reported in case reports, and there is a scarcity of relevant systematic reviews. The aim of the current study was to analyze and summarize the clinical characteristics of patients diagnosed with HEV-induced hemolytic anemia. Methods: This study included 1 patient diagnosed with HEV-induced hemolytic anemia who was admitted to our hospital and 19 additional patients identified through the available literature. Results: Of the 20 patients included in this study, the majorities were from China and India (12 and 6 cases, respectively); furthermore, 13 of them were men and 7 were women, with an average age of 35 (16-56) years. The highest total bilirubin level was 646 (452-913) μmol/L, highest alanine aminotransferase level was 1335 (708-2798) IU/L, and lowest hemoglobin level was 6.0 ± 2.0 g/dL. Additionally, 10 patients (50.0%, 10/20) underwent the glucose-6-phosphate dehydrogenase (G6PD) activity test, and all of them were diagnosed with G6PD deficiency (100.0%, 10/10). Finally, 18 patients (90.0%) recovered and 2 died (10.0%) after treatment. Conclusions: Most of the patients with HEV-induced hemolytic anemia recovered with treatment. Acute HEV infection that causes hemolytic anemia is strongly associated with the G6PD status of the patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.